Bile acid malabsorption

Bile acid diarrhea / Bile acid malabsorption
Other namesBile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea, bile salt malabsorption
SpecialtyGastroenterology
SymptomsBowel movement frequency, soft or watery stools, diarrhea, urgency[1]
ComplicationsAnxiety, fecal incontinence
Usual onsetAny age
DurationChronic (longlasting, persistent)
TypesPrimary or secondary or types 1,2 and 3
CausesSurgical resection of ileum, cholecystectomy, idiopathic
Risk factorsPelvic radiation disease, small intestinal bacterial overgrowth
Diagnostic methodFecal bile acids, SeHCAT, 7α-hydroxy-4-cholesten-3-one
Differential diagnosisIrritable bowel syndrome, microscopic colitis
MedicationBile acid sequestrants
PrognosisGood with treatment
Frequency1 in 100 of population
DeathsNon-fatal

Bile acid malabsorption (BAM), known also as bile acid diarrhea, is a cause of several gut-related problems, the main one being chronic diarrhea. It has also been called bile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea or bile salt malabsorption. It can result from malabsorption secondary to gastrointestinal disease, or be a primary disorder, associated with excessive bile acid production. Treatment with bile acid sequestrants is often effective.

Signs and symptoms

A persistent (chronic) history of diarrhea, with watery or mushy, unformed stools, (types 6 and 7 on the Bristol stool scale), sometimes with steatorrhea, increased frequency and urgency of defecation are common manifestations, often with fecal incontinence and other gastrointestinal symptoms such as abdominal swelling, bloating and abdominal pain.[2][3][1][4]

People with this disorder often report impairments of mental health and well-being, including fatigue, dizziness, anxiety about leaving home (primarily due to fear of fecal incontinence), depression, one survey reports.[1] It contributes in delays in diagnosis.[1]

Pathogenesis

Enterohepatic circulation of bile salts

Bile acids (also called bile salts) are produced in the liver, secreted into the biliary system, stored in the gallbladder and are released after meals stimulated by cholecystokinin. They are important for the digestion and absorption of fats (lipids) in the small intestine. Usually over 95% of the bile acids are absorbed in the terminal ileum and are taken up by the liver and resecreted. This enterohepatic circulation of bile acids takes place 4-6 times in 24 hours and usually less than 0.5 g of bile acids enter the large intestine per 24 h. When larger amounts of bile acids enter the large intestine, they stimulate water secretion and intestinal motility in the colon, which causes symptoms of chronic diarrhea.[5]

Intestinal absorption of bile acids

The ileum is very efficient at absorbing the glyco- and taurine-conjugated forms of the bile salts. The apical sodium-dependent bile salt transporter (ASBT, IBAT, gene symbol SLC10A2) is the first step in absorption at the brush-border membrane. The cytoplasmic ileal bile acid binding protein (IBABP, ILBP, gene symbol FABP6) and the basolateral heterodimer of OSTα and OSTβ transfer bile acids through and out of the cell where they eventually enter the portal vein. These bile acid transporters are all highly expressed in the ileum but not in the liver, jejunum or colon.[6] When expression of these specialized transporters is reduced, the intestine is less efficient at bile acid reabsorption (Type 1 bile acid malabsorption). If intestinal motility is affected by gastro-intestinal surgery, or bile acids are deconjugated by small intestinal bacterial overgrowth, absorption is less efficient (Type 3 bile acid malabsorption). A very small proportion of the patients with no obvious disease (Type 2 bile acid malabsorption) may have mutations in ASBT,[7] but this mutation is not more common in most patients and does not affect function.[8]

Overproduction of bile acids

Primary bile acid diarrhea (Type 2 bile acid "malabsorption") may be caused by an overproduction of bile acids.[5][9] Several groups of workers have failed to show any defect in ileal bile acid absorption in these patients, and they have an enlarged bile acid pool, rather than the reduced pool expected with malabsorption.[10] The synthesis of bile acids in the liver is negatively regulated by the ileal hormone fibroblast growth factor 19 (FGF19), and lower levels of this hormone result in overproduction of bile acids, which are more than the ileum can absorb.[9]

Diagnosis

Several methods have been developed to identify the disorder but there are difficulties with all of them.[11] Diagnosis of bile acid malabsorption is easily and reliably made by the SeHCAT test. This nuclear medicine test involves two scans a week apart and so measures multiple cycles of bile acid excretion and reabsorption. There is limited radiation exposure (0.3 mSv). Retention of SeHCAT at 7 days is normally above 15%; values less than 15%, 10% and 5% predict respectively mild, moderate and severe abnormal retention and an increasing likelihood of response to bile acid sequestrants.[12] This test is not licensed in the USA, and is underutilized even where it is available.[13][14] Older methods such as the 14C-glycocholic breath test are no longer in routine clinical use.

Measurement of 7α-Hydroxy-4-cholesten-3-one, (C4), a bile acid precursor, in serum, shows the increased bile acid synthesis found in bile acid malabsorption.[15] This test is an alternative diagnostic means when available. Fasting blood FGF19 values may have value in the recognition of the disease and prediction of response.[16]

The various biomarkers give similar diagnostic yields of around 25% in patients with functional bowel disorders with diarrhea.[17] In countries such as the USA, where SeHCAT is not available, fecal bile acids and C4 are available to make the diagnosis.[17]

Classification

Bile acid malabsorption was first recognized in patients with ileal disease.[18] When other causes were recognized, and an idiopathic, primary form described,[19] a classification into three types was proposed:[20]

Treatment

Bile acid sequestrants are the main agents used to treat bile acid malabsorption.[21] Cholestyramine and colestipol, both in powder form, have been used for many years. Unfortunately, many patients find them difficult to tolerate; although the diarrhea may improve, other symptoms such as abdominal pain and bloating may worsen. Colesevelam is a tablet and some patients tolerate this more easily.[22][23][24] A proof of concept study of the farnesoid X receptor agonist obeticholic acid has shown clinical and biochemical benefit.[25] As of March 15, 2016, Novartis Pharmaceuticals is conducting a phase II clinical study involving a farnesoid X receptor agonist named LJN452.[26]

Epidemiology

Bile acid malabsorption is common in Crohn's disease but not always recognized. Most people with previous ileal resection and chronic diarrhea will have abnormal SeHCAT tests and can benefit from bile acid sequestrants.[4]

People with primary bile acid diarrhea are frequently misdiagnosed as having irritable bowel syndrome.[13] When SeHCAT testing is performed, the diagnosis of primary bile acid diarrhea is commonly made. In a review of 18 studies of the use of SeHCAT testing in diarrhea-predominant irritable bowel syndrome patients, 32% of 1223 people had a SeHCAT 7-day retention of less than 10%, and 80% of these reported a response to cholestyramine, a bile acid sequestrant.[12]

Estimates of the population prevalence suggest that 1% of the adult population could have primary bile acid diarrhea (Type 2 bile acid malabsorption).[12]

References

  1. 1 2 3 4 Bannaga, A; Kelman, L; O'Connor, M; Pitchford, C; Walters, JR; Arasaradnam, RP (2017). "How bad is bile acid diarrhoea: an online survey of patient-reported symptoms and outcomes". BMJ Open Gastroenterology. 4 (1): e000116. doi:10.1136/bmjgast-2016-000116. PMC 5253456. PMID 28123771.
  2. ↑ Zhang, Lizhi; Chandan, Vishal S.; Wu, Tsung-Teh (2019). Surgical Pathology of Non-neoplastic Gastrointestinal Diseases. Springer. p. 226. ISBN 978-3-030-15573-5.
  3. ↑ Vijayvargiya P, Camilleri M (March 2018). "Update on Bile Acid Malabsorption: Finally Ready for Prime Time?". Current Gastroenterology Reports. 20 (3): 10. doi:10.1007/s11894-018-0615-z. PMID 29582208. S2CID 4419631.
  4. 1 2 Sadowski, DC; Camilleri, M; Chey, WD; Leontiadis, GI; Marshall, JK; Shaffer, EA; Tse, F; Walters, JRF (January 2020). "Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea". Clinical Gastroenterology and Hepatology. 18 (1): 24–41.e1. doi:10.1016/j.cgh.2019.08.062. PMID 31526844.
  5. 1 2 Hofmann AF (October 2009). "Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last". Expert Review of Gastroenterology & Hepatology. 3 (5): 461–4. doi:10.1586/egh.09.49. PMID 19817666.
  6. ↑ Dawson, PA; Lan, T; Rao, A (2009). "Bile acid transporters". Journal of Lipid Research. 50 (12): 2340–57. doi:10.1194/jlr.R900012-JLR200. PMC 2781307. PMID 19498215.
  7. ↑ Oelkers, P; Kirby, LC; Heubi, JE; Dawson, PA (1997). "Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2)". The Journal of Clinical Investigation. 99 (8): 1880–7. doi:10.1172/JCI119355. PMC 508012. PMID 9109432.
  8. ↑ Montagnani, M; Love, MW; Rössel, P; Dawson, PA; Qvist, P (2001). "Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption". Scandinavian Journal of Gastroenterology. 36 (10): 1077–80. doi:10.1080/003655201750422693. PMID 11589382.
  9. 1 2 Walters, JR; Tasleem, AM; Omer, O S; Brydon, WG; Dew, T; le Roux, CW (2009). "A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis". Clinical Gastroenterology and Hepatology. 7 (11): 1189–94. doi:10.1016/j.cgh.2009.04.024. PMID 19426836.
  10. ↑ van Tilburg, AJ; de Rooij, FW; van den Berg, JW; van Blankenstein, M (1992). "Primary bile acid malabsorption: a pathophysiologic and clinical entity?". Scandinavian Journal of Gastroenterology. Supplement. 194: 66–70. doi:10.3109/00365529209096030. PMID 1298051.
  11. ↑ Vijayvargiya P, Camilleri M, Shin A, Saenger A (2013). "Methods for diagnosis of bile acid malabsorption in clinical practice". Clin. Gastroenterol. Hepatol. 11 (10): 1232–9. doi:10.1016/j.cgh.2013.04.029. PMC 3783593. PMID 23644387.
  12. 1 2 3 Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ (2009). "Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome". Aliment. Pharmacol. Ther. 30 (7): 707–17. doi:10.1111/j.1365-2036.2009.04081.x. PMID 19570102. S2CID 11327665.
  13. 1 2 Walters, JR (2010). "Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder". Expert Review of Gastroenterology & Hepatology. 4 (5): 561–7. doi:10.1586/egh.10.54. PMID 20932141. S2CID 27123642.
  14. ↑ Khalid, U; Lalji, A; Stafferton, R; Andreyev, J (2010). "Bile acid malabsorption: a forgotten diagnosis?". Clinical Medicine. 10 (2): 124–6. doi:10.7861/clinmedicine.10-2-124. PMC 4952080. PMID 20437979.
  15. ↑ Brydon, WG; Nyhlin, H; Eastwood, MA; Merrick, MV (1996). "Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea". European Journal of Gastroenterology & Hepatology. 8 (2): 117–23. doi:10.1097/00042737-199602000-00005. PMID 8723414. S2CID 23867181.
  16. ↑ Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas M, Basumani P, Bardhan KD, Walters JR (2013). "Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention". Aliment. Pharmacol. Ther. 38 (8): 967–76. doi:10.1111/apt.12466. PMID 23981126. S2CID 6386339.
  17. 1 2 Valentin, N; Camilleri, M; Altayar, O; Vijayvargiya, P; Acosta, A; Nelson, AD; Murad, MH (December 2016). "Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis". Gut. 65 (12): 1951–1959. doi:10.1136/gutjnl-2015-309889. PMID 26347530. S2CID 3454888.
  18. ↑ Hofmann, AF (1967). "The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy". Gastroenterology. 52 (4): 752–7. doi:10.1016/S0016-5085(67)80140-9. PMID 5337211.
  19. ↑ Thaysen, EH; Pedersen, L (1976). "Idiopathic bile acid catharsis". Gut. 17 (12): 965–70. doi:10.1136/gut.17.12.965. PMC 1411224. PMID 1017717.
  20. ↑ Fromm, H; Malavolti, M (1986). "Bile acid-induced diarrhoea". Clinics in Gastroenterology. 15 (3): 567–82. doi:10.1016/S0300-5089(21)00739-2. PMID 3742841.
  21. ↑ Wilcox C, Turner J, Green J (May 2014). "Systematic review: the management of chronic diarrhoea due to bile acid malabsorption". Aliment. Pharmacol. Ther. 39 (9): 923–39. doi:10.1111/apt.12684. PMID 24602022. S2CID 12016216.
  22. ↑ Wedlake, L; Thomas, K; Lalji, A; Anagnostopoulos, C; Andreyev, HJ (2009). "Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire". Clinical Therapeutics. 31 (11): 2549–58. doi:10.1016/j.clinthera.2009.11.027. PMID 20109999.
  23. ↑ NICE. "Bile acid malabsorption: colesevelam". Retrieved 17 August 2014.
  24. ↑ Beigel F, Teich N, Howaldt S, Lammert F, Maul J, Breiteneicher S, Rust C, Göke B, Brand S, Ochsenkühn T (November 2014). "Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study". J Crohns Colitis. 8 (11): 1471–9. doi:10.1016/j.crohns.2014.05.009. PMID 24953836.
  25. ↑ Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA (January 2015). "The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid". Aliment. Pharmacol. Ther. 41 (1): 54–64. doi:10.1111/apt.12999. hdl:10044/1/21617. PMID 25329562. S2CID 44661338.
  26. ↑ "To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea. - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 9 April 2018.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.